X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs STRIDES PHARMA SCIENCE - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS STRIDES PHARMA SCIENCE NOVARTIS/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 290.4 51.8 560.3% View Chart
P/BV x 32.2 1.1 2,852.0% View Chart
Dividend Yield % 1.4 0.4 329.9%  

Financials

 NOVARTIS   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    NOVARTIS
Mar-18
STRIDES PHARMA SCIENCE
Mar-18
NOVARTIS/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs7581,147 66.1%   
Low Rs579642 90.2%   
Sales per share (Unadj.) Rs228.4317.2 72.0%  
Earnings per share (Unadj.) Rs31.77.8 404.6%  
Cash flow per share (Unadj.) Rs32.825.1 130.8%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.2 669.0%  
Book value per share (Unadj.) Rs297.1274.3 108.3%  
Shares outstanding (eoy) m24.6989.50 27.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.8 103.8%   
Avg P/E ratio x21.1114.0 18.5%  
P/CF ratio (eoy) x20.435.7 57.2%  
Price / Book Value ratio x2.23.3 69.0%  
Dividend payout %31.525.5 123.6%   
Avg Mkt Cap Rs m16,50580,058 20.6%   
No. of employees `0000.72.5 26.6%   
Total wages/salary Rs m1,4454,341 33.3%   
Avg. sales/employee Rs Th8,441.311,325.8 74.5%   
Avg. wages/employee Rs Th2,163.61,731.4 125.0%   
Avg. net profit/employee Rs Th1,173.1280.1 418.9%   
INCOME DATA
Net Sales Rs m5,63928,394 19.9%  
Other income Rs m1,718941 182.7%   
Total revenues Rs m7,35729,334 25.1%   
Gross profit Rs m-633,965 -1.6%  
Depreciation Rs m251,540 1.6%   
Interest Rs m551,962 2.8%   
Profit before tax Rs m1,5751,403 112.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m79297 813.6%   
Profit after tax Rs m784702 111.6%  
Gross profit margin %-1.114.0 -7.9%  
Effective tax rate %50.36.9 724.7%   
Net profit margin %13.92.5 562.0%  
BALANCE SHEET DATA
Current assets Rs m9,52224,836 38.3%   
Current liabilities Rs m3,29618,993 17.4%   
Net working cap to sales %110.420.6 536.5%  
Current ratio x2.91.3 220.9%  
Inventory Days Days3771 51.6%  
Debtors Days Days28113 25.1%  
Net fixed assets Rs m4634,289 0.1%   
Share capital Rs m123895 13.8%   
"Free" reserves Rs m7,21323,651 30.5%   
Net worth Rs m7,33624,546 29.9%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m11,10565,437 17.0%  
Interest coverage x29.51.7 1,719.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.50.4 117.0%   
Return on assets %7.64.1 185.5%  
Return on equity %10.72.9 373.4%  
Return on capital %22.26.9 322.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6115,697 0.4%   
Fx outflow Rs m3,630735 493.6%   
Net fx Rs m-3,57014,962 -23.9%   
CASH FLOW
From Operations Rs m1,6101,871 86.1%  
From Investments Rs m6875,826 11.8%  
From Financial Activity Rs m-2,677-10,157 26.4%  
Net Cashflow Rs m-380-2,615 14.5%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 37.8 5.3%  
FIIs % 1.6 8.6 18.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 25.9 83.0%  
Shareholders   41,647 56,241 74.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare NOVARTIS With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 16, 2018 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - BIOCON LTD COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS